

Amendments to the Specification

Please insert the following added paragraph before the paragraph beginning on page 1, line 3 of the Application as originally filed. This added paragraph is thus to be inserted as the first paragraph of the Specification:

This application is a U.S. National Phase application of PCT/US2004/018783, filed June 14, 2004, which claims the benefit of U.S. Provisional Application No. 60/478,521, filed June 13, 2003.

Please insert the following added paragraph immediately after the preceding added paragraph provided above. This added paragraph is thus to be inserted as the second paragraph of the Specification:

A Computer Readable Form of the Sequence Listing (on file “50664 Seq Listing_ST25.txt”, created on January 7, 2009 and which is 727 bytes as measured in MS-WINDOWS operating system) is incorporated herein by reference.

Please replace the paragraph under the heading “Figure 3: Diagram of the MP295 replicon cDNA,” beginning on page 4, line 2 of the Application as originally filed with the following amended paragraph:

The *bsd* gene was inserted into YM6 to generate the replicon cDNA, MP295. The sequence flanking the *bsd* gene is indicated in this diagram. The upstream flanking sequence comprising IG-M/SH and PvuI sequences is SEQ ID NO:1. The downstream flanking sequence comprising

XhoI and IG-F/M2 sequences is SEQ ID NO:2. To produce replicon RNA during the launch process (Figs. 1 and 4), the T7 polymerase initiates transcription at the T7 promoter and produces full-length antigenomic RNA, terminated at the T7 terminators. The ribozyme sequence then cleaves itself from the transcript.

Please enter the accompanying Sequence Listing into the application in accordance with 37 C.F.R. §§ 1.821-1.825.